Minimal Residual Disease and Survival Outcomes in Patients with Mantle Cell Lymphoma: a systematic review and meta-analysis.

Minimal residual disease (MRD) has shown the prognostic value in mantle cell lymphoma (MCL). To quantify the relationships between progression free survival (PFS) and overall survival (OS) with MRD status in MCL, we conducted this meta-analysis. We searched databases including Pubmed, Embase, Web of Science and the Cochrane Library up to July 15, 2020. Data of patients' characteristics, MRD assessment and survival outcomes were extracted and analyzed. Ten articles were included. For the impact of post-induction MRD status on survival outcomes, MRD positive status was associated with worse PFS (HR=1.44; 95%CI 1.27-1.62; <0.00001) and OS (HR=1.30; 95%CI 1.03-1.64; =0.03) compared with MRD negative status. Regarding the impact of post-consolidation MRD status on survival outcomes, MRD positivity predicted shorter PFS (HR=1.84; 95%CI 1.49-2.26; <0.00001) and OS (HR=2.38; 95%CI 1.85-3.06; <0.00001) than MRD negativity. This study indicated that MRD positivity after induction and consolidation treatments was associated with worse PFS and OS for MCL. MRD-based treatment strategies should be further explored in clinical trials and real-world practice.